New Data in Patients With Psoriasis With High-Impact Site Involvement

Panelists discuss how patients similar to those in the SPECTREM trial—individuals with limited body surface area (BSA) but significant disease in high-impact areas like the scalp, face, hands, feet, or genitals—represent a substantial and often undertreated population in everyday practice, highlighting the importance of recognizing that these patients with moderate psoriasis frequently experience disproportionate quality-of-life impairment despite not meeting traditional severity thresholds, potentially benefiting from earlier biologic intervention as demonstrated in the guselkumab study.